Lumbosacral spinal stenosis. Spinal stenosis, lumbar region
Conditions
Interventions
Intervention 1: Intervention group: will receive hyalorunidase 1500 IU , methylprednisolone 80 mg, and marcaine 4cc.the injection will be done under fluoroscopic guide and after contrast media inject
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with lumbosacral spinal stenosis who have pain and other clinical symptoms didn’t respond to conservative management Age between 45 to 75 y/o Complete and sign constent form Exclusion
Exclusion criteria
Exclusion criteria: Diabetes mellitus Rheumatologic disease such as collagen vascular disease , SLE , gout Simultaneous radiculopathy Simultaneous neuropathy Brucella infection BMI> 42 Knee arthroplasty in affected side Coaglopathy Inability to complete questionnaire and poor cooperation Allergy to medication Hepatic , renal or cardiac failure Pregnancy Cancer Patients who are receiving Anticoagulant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient's pain. Timepoint: Before injection , 2, 4 and 8 weeks after injection. Method of measurement: Visual Analogue Scale , Quebec back pain disability scale and Oswestry disability index questionnaire.;Functional improvement. Timepoint: Before injection , 2, 4 and 8 weeks after injection. Method of measurement: Quebec back pain disability scale and Oswestry disability index questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| ?Quality of life improvement. Timepoint: Befor injection , 2, 4 and 8 weeks after injection. Method of measurement: Quebec back pain disability scale and Oswestry disability index questionnaire.;Decrease analgesic usage. Timepoint: Before injection , 2, 4 and 8 weeks after injection. Method of measurement: Visual Analogue Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Alireza Ashraf
Shiraz University of Medical Sciences
Outcome results
None listed